~~<i id='969FA05095'><strike id='969FA05095'><tt id='969FA05095'><pre id='969FA05095'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：comprehensive 2025-09-29 11:14:57 Page View：656

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Spinal cord stimulation reduces pain in amputees, study finds
Next article： Affirmative action in medical school literally saved lives

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

DrugmakersalreadybetbigonmRNAforcancer.NowPresidentBidenisgoingin,too?AnnaMoneymaker/GettyImagesWASH

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

STEFANIREYNOLDS/AFPviaGettyImagesUnderstandhowscience,healthpolicy,andmedicineshapetheworldeveryday.